Future of Genomic Testing in Lung Cancer

The final segment of the program addresses the practical realities and future outlook of genomic testing in lung cancer. The panel begins by discussing the financial and access related challenges that often accompany molecular testing, including insurance coverage, prior authorizations, and differences in test availability across institutions and geographic regions. Dr Husain and Dr Singhal explain how these barriers can delay care and sometimes limit a patient’s ability to receive the most appropriate targeted therapy. They describe how they navigate these issues in their own practices, using institutional pathways, laboratory support services, and payer engagement to help ensure that patients receive timely and comprehensive testing.

The discussion then turns to how clinicians talk with patients about cost and value. The experts emphasize that genomic testing is not simply an added expense but a tool that can prevent ineffective treatment, reduce unnecessary toxicity, and improve outcomes by guiding therapy more precisely. Clear communication about the role of testing helps patients understand why molecular profiling is a critical part of modern lung cancer care.

Looking ahead, the panel reflects on how genomic testing will continue to shape the future of lung cancer management. They anticipate faster turnaround times, broader and more sensitive panels, and better integration of molecular data into clinical workflows. The program concludes with a message to community oncologists to remain engaged with evolving testing strategies, as precision medicine will continue to drive how lung cancer is diagnosed, monitored, and treated in the years to come.